Lynch Asset Management’s AbbVie ABBV Stock Holding History

Lynch Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$9.86M	Sell	45,350 -300	-0.7%	-$66.5K	3.31%	6
2025 Q4	$10.4M	Sell	45,650 -200	-0.4%	-$45.6K	3.28%	5
2025 Q3	$10.6M	Hold	45,850	–	–	3.4%	4
2025 Q2	$8.51M	Hold	45,850	–	–	3%	6
2025 Q1	$9.61M	Hold	45,850	–	–	4.31%	4
2024 Q4	$8.15M	Hold	45,850	–	–	3.3%	8
2024 Q3	$9.05M	Hold	45,850	–	–	3.81%	5
2024 Q2	$7.86M	Hold	45,850	–	–	3.36%	8
2024 Q1	$8.35M	Sell	45,850 -1,500	-3%	-$259K	3.93%	5
2023 Q4	$7.34M	Sell	47,350 -500	-1%	-$72.9K	4.21%	5
2023 Q3	$7.13M	Sell	47,850 -2,500	-5%	-$367K	4.69%	4
2023 Q2	$6.78M	Sell	50,350 -500	-1%	-$73.3K	4.36%	5
2023 Q1	$8.1M	Hold	50,850	–	–	5.81%	3
2022 Q4	$8.22M	Hold	50,850	–	–	7.08%	2
2022 Q3	$6.83M	Hold	50,850	–	–	6.13%	3
2022 Q2	$7.79M	Hold	50,850	–	–	6.37%	3
2022 Q1	$8.24M	Hold	50,850	–	–	5.89%	3
2021 Q4	$6.89M	Buy	+50,850	New	+$6.01M	4.78%	5

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Lynch Asset Management's ABBV Position: Q1 2026 in Review

Lynch Asset Management reduced its AbbVie (ABBV) stake by 0.66% in Q1 2026, selling an estimated $66.5K and leaving 45,350 shares worth $9.86M. The position accounts for 3.31% of the portfolio, ranked #6.

Lynch Asset Management first reported a position in ABBV in Q4 2021 and has held it in 18 quarters since. The position peaked at $10.6M in Q3 2025. 4,076 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Lynch Asset Management held 45,350 shares of AbbVie worth $9.86M as of Q1 2026.
Lynch Asset Management sold 300 AbbVie shares in Q1 2026, an estimated $66.5K.
AbbVie made up 3.31% of Lynch Asset Management's portfolio in Q1 2026, its #6 holding.
Lynch Asset Management first reported a position in AbbVie in Q4 2021 and has held it in 18 quarters since.
Lynch Asset Management's AbbVie position peaked at $10.6M in Q3 2025.
4,076 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Lynch Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.